Patents by Inventor Neta Erez
Neta Erez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230210814Abstract: The invention provides a method for treating or preventing brain metastases comprising the step of administering to a patient in need a composition comprising a therapeutically effective amount of LCN2 Inhibitor, an agent that interferes in systemic LCN2 signaling pathways, or an agent that reduces LCN2 expression or any combination thereof.Type: ApplicationFiled: February 17, 2023Publication date: July 6, 2023Inventors: Neta EREZ, Hila Doron, Omer Adler
-
Publication number: 20150297693Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: ApplicationFiled: June 30, 2015Publication date: October 22, 2015Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Johannes HERKEL, Irun R. COHEN, Varda ROTTER, Ansgar W. LOHSE, Neta EREZ, Avishai MIMRAN, Na'aman KAM
-
Publication number: 20140329758Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: ApplicationFiled: July 27, 2014Publication date: November 6, 2014Inventors: JOHANNES KERKEL, IRUN R. COHEN, VARDA ROTTER, ANSGAR W. LOHSE, NETA EREZ, AVISHAI MIMRAN, NA'AMAN KAM
-
Patent number: 8790653Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: GrantFiled: November 1, 2011Date of Patent: July 29, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Publication number: 20120171233Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: ApplicationFiled: November 1, 2011Publication date: July 5, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. at The Weizmann Institute of ScienceInventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Patent number: 8067008Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: GrantFiled: August 23, 2005Date of Patent: November 29, 2011Assignee: YEDA Research and Development Co.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Publication number: 20090098116Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.Type: ApplicationFiled: November 20, 2007Publication date: April 16, 2009Applicant: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel
-
Publication number: 20080267983Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides.Type: ApplicationFiled: August 23, 2005Publication date: October 30, 2008Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Patent number: 7378092Abstract: The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.Type: GrantFiled: May 16, 2005Date of Patent: May 27, 2008Assignee: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel
-
Patent number: 7118744Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.Type: GrantFiled: January 2, 2002Date of Patent: October 10, 2006Assignee: Yeda Research and Development Co., Ltd.Inventors: Irun R Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel
-
Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
Publication number: 20060030524Abstract: Systemic lupus erythematosus (SLE) can be prevented or treated by down-regulating the autoimmune response to the C-terminal-DNA-binding domain of the p53 protein (p53) by an active principle selected from the group consisting of: (i) a peptide of, or comprising, the C-terminal DNA-binding domain of the p53 protein; (ii) a monoclonal antibody (mAb) specific for said domain of p53 (Ab1), and fragments thereof; (iii) an mAb specific for Ab1 (hereinafter Ab2), and fragments thereof; (iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2; (v) a DNA molecule coding for (i) and (iv) of for the variable region of said Ab1 and Ab2 of (ii) and (iii); and (vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR. SLE can also be diagnosed by assaying for antibodies (Ab1) against the C-terminal DNA-binding domain of p53 or antibodies (Ab2) specific to the Ab1 antibodies.Type: ApplicationFiled: July 13, 2005Publication date: February 9, 2006Applicant: Yeda Research and Development Co. Ltd.Inventors: Irun Cohen, Varda Rotter, Neta Erez, Johannes Herkel -
Publication number: 20050208065Abstract: The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.Type: ApplicationFiled: May 16, 2005Publication date: September 22, 2005Inventors: Irun Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel
-
Publication number: 20020197270Abstract: The invention relates to the use of an immunogen selected from the group consisting ofType: ApplicationFiled: January 2, 2002Publication date: December 26, 2002Applicant: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel